Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Valbenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
- 03 Aug 2017 Status changed from recruiting to completed, according to a Neurocrine Biosciences media release.
- 09 May 2017 According to a Neurocrine Biosciences media release, the Company announced that in July 2017 it plans to complete this roll-over study.
- 10 Oct 2016 Planned number of patients changed from 75 to 150.